Sonnet BioTherapeutics (formerly known as Chanticleer Holdings) is an oncology-focused biotechnology company. It develops a platform for biologic medicines of single- or bi-specific actions and provides FHAB (fully human albumin binding) drug accumulation improvement technology. The FHAB technology serves immunotherapy, drug conjugation, vaccine developers, and chimeric antigen receptor T cells (CAR T-cell) therapy.